1. Scrip
  2. >>Business
  3. >>Deals

Vertex Targeting Protein Degradation In $1bn Kymera Deal

 
• By John Davis

Vertex and Kymera will use insights into the ubiquitin-proteasome pathway, for sending unwanted proteins off to recycling, to discover new drug candidates.  

RubbishBags
A new therapeutic approach involves using the way cells tag unwanted proteins for recycling • Source: Shutterstock

New treatment modalities are rare in pharma R&D, but Vertex Pharmaceuticals Inc. has joined the buzz surrounding the development of novel medicines targeting protein degradation by linking up with Kymera Therapeutics Inc. to discover small-molecule protein degraders for use against multiple diseases.

Cambridge, MA-based Kymera has already attracted GlaxoSmithKline PLC as a collaborator, in a deal signed in April 2018, and other pharma companies said to be interested in targeting protein degradation for novel products include Celgene Corp., Genentech Inc., AbbVie Inc. and C4 Therapeutics Inc.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.